Trial
NCT05237713
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Leipzig
Collaborators
Novartis Pharmaceuticals
Condition
Anemia
Intervention
Canakinumab Injection
Why stopped
Slow recruitment. It is not considered likely that the CANFIRE trial will be able to reach the target number of patients. Clinical responders will be further treated within the trial (expected duration: 3 years after stop of enrollment).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-06